Detalhe da pesquisa
1.
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.
Genome Res
; 27(4): 613-625, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28179366
2.
Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy.
Ultrastruct Pathol
; 43(6): 237-247, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31810413
3.
Predictors of Metachronous Risk Polyps After Index Colonoscopy.
Clin Transl Gastroenterol
; 12(2): e00304, 2021 02 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33605613
4.
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Clin Cancer Res
; 15(10): 3530-9, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19417026
5.
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Lung Cancer
; 140: 42-45, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31862576
6.
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Mol Cancer Ther
; 18(11): 2135-2145, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31484705
7.
Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
Cancer Cytopathol
; 126(10): 860-871, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30291816
8.
Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.
Clin Lung Cancer
; 19(5): 387-394.e2, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29656868
9.
Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
J Med Case Rep
; 10(1): 158, 2016 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27255157
10.
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Clin Cancer Res
; 22(13): 3260-7, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26888827
11.
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
Clin Cancer Res
; 21(9): 2157-66, 2015 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25623215
12.
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Oncotarget
; 5(1): 196-210, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24344116
13.
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
Eur J Cancer
; 50(15): 2725-34, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25128455
14.
Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer.
PLoS One
; 7(5): e38347, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22675457
15.
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Nat Med
; 18(2): 221-3, 2012 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-22270724
16.
[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. / Uso de tratamientos contra diana en Oncología y su impacto en el diseño de estudios clínicos: los receptores del factor de crecimiento epidérmico 1 y 2 como paradigma.
Med Clin (Barc)
; 141(4): 176-80, 2013 Aug 17.
Artigo
em Espanhol
| MEDLINE | ID: mdl-23809407
17.
Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.
Cell Cycle
; 6(18): 2284-92, 2007 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17890907
18.
Uso de tratamientos contra diana en Oncología y su impacto en el diseño de estudios clínicos: los receptores del factor de crecimiento epidérmico 1 y 2 como paradigma / The use of targeted therapies in Oncology and their impact in the design of clinical trials: Epidermal growth factor receptors 1 and 2 as a paradigm
Med. clín (Ed. impr.)
; 141(4): 176-180, ago. 2013.
Artigo
em Espanhol
| IBECS (Espanha) | ID: ibc-114422